Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2066930 | 0.78 | HPGD (0.43) | MAPTKMT2AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL15823928 | 0.77 | HSD11B1 (0.33) | NPC1RAB9A | |
| SCHEMBL15414290 | 0.76 | CYP17A1 (0.34) | MAPTKMT2AALDH1A1KDM4EALOX15 | |
| SCHEMBL2068642 | 0.75 | TLR8 (0.38) | MAPTKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL4232724 | 0.75 | — | — | |
| SCHEMBL5218807 | 0.71 | NPC1 (0.45) | MAPTKMT2AALDH1A1KDM4EALOX15 | |
| SCHEMBL4397933 | 0.70 | CYP17A1 (0.51) | MAPTKMT2AALDH1A1KDM4EALOX15 | |
| SCHEMBL17046430 | 0.70 | MEN1 (0.43) | MAPTKMT2AALDH1A1KDM4EALOX15 | |
| SCHEMBL587874 | 0.70 | TAAR1 (0.33) | — | |
| SCHEMBL14938524 | 0.69 | ALDH1A1 (0.30) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108164507-A | A kind of R-lansoprazole monocrystalline and its preparation method and application | 天津药物研究院有限公司 | 2018-06-15 | — | — | CN | claimed |
| WO-2009106745-A2 | METHOD FOR ENANTIO-SELECTIVE PREPARATION OF SULPHOXIDES | SIDEM PHARMA SA (LU) | 2009-09-03 | — | — | WO | claimed |
| CN-107202893-B | A kind of small molecule chip, its construction method, its application and its detection method | 广州高通生物技术有限公司 | 2019-08-13 | — | — | CN | disclosed |
| CN-109111430-A | A kind of Dexlansoprazole crystal form A and preparation method thereof | 江苏豪森药业集团有限公司 | 2019-01-01 | — | — | CN | disclosed |
| EP-2277510-B1 | Controlled release preparation | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-26 | — | — | EP | disclosed |
| EP-2275088-B2 | Method for producing granules | TAKEDA PHARMACEUTICALS CO (JP) | 2018-09-26 | — | — | EP | disclosed |
| CN-104080446-B | Dry coated tablets | 武田药品工业株式会社 | 2018-06-29 | — | — | CN | disclosed |
| CN-107011252-B | The method for drawing azole intermediate and drug is prepared using the green technology for substituting the poisonous and harmful substances such as phosgene, thionyl chloride | 浙江工业大学 | 2018-06-08 | — | — | CN | disclosed |
| CN-104530018-B | Indole compounds containing alpha-methylene-gamma-butyrolactone structures, preparation method and application thereof | 郑州大学 | 2017-04-12 | — | — | CN | disclosed |
| EP-1602362-B1 | DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE | TAKEDA PHARMACEUTICAL (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2016-05-12 | — | — | US | disclosed |
| EP-1607088-A1 | CONTROLLED RELEASE COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2005-12-21 | — | — | EP | disclosed |
| EP-1602362-A1 | DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE | Takeda Pharmaceutical Company Limited (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-20050222210-A1 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1553929-A2 | CONTROLLED RELEASE PREPARATION | Takeda Pharmaceutical Company Limited (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1513527-A1 | PRODRUGS OF IMIDAZOLE DERIVATIVES, FOR USE AS PROTON PUMP INHIBITORS IN THE TREATMENT OF E.G. PEPTIC ULCERS | Takeda Pharmaceutical Company Limited (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1514870-A1 | PRODRUG AND PROCESS FOR PRODUCING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004035020-A2 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003105845-A1 | PRODRUGS OF IMIDAZOLE DERIVATIVES, FOR USE AS PROTON PUMP INHIBITORS IN THE TREATMENT OF E.G. PEPTIC ULCERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-12-24 | — | — | WO | disclosed |
| US-6423846-B1 | USING PHASE TRANSFER CATALYST | HANMI PHARM. CO., LTD. (KR) | 2002-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222210-A1 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | SI, VIP, PGC | MAPT 4193/4885KMT2A 2419/4885ALDH1A1 302/4885 |
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | MAPT 1399/4885KMT2A 4068/4885ALDH1A1 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.